Mateon Therapeutics, Inc. (OTCMKTS:MATN – Get Free Report)’s share price crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $0.03 and traded as high as $0.04. Mateon Therapeutics shares last traded at $0.04, with a volume of 365,510 shares trading hands.
Mateon Therapeutics Stock Performance
The firm has a 50 day moving average price of $0.02 and a 200 day moving average price of $0.03.
Mateon Therapeutics Company Profile
Mateon Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.
See Also
- Five stocks we like better than Mateon Therapeutics
- Technology Stocks Explained: Here’s What to Know About Tech
- Is McDonald’s Stock a Smart Buy After Sell-Off and Earnings?
- What Investors Need to Know About Upcoming IPOs
- QuantumScape: Solid State EV Batteries Nearing Commercialization
- Airline Stocks – Top Airline Stocks to Buy Now
- MicroStrategy: Is This Bitcoin-Powered Stock a Buy or a Gamble?
Receive News & Ratings for Mateon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
